WEBINAR ON DEMAND
Duration: 1 hour

Cell and gene therapies (CGT) hold the promise of improved outcomes—and even the possibility of a cure—for previously uncurable diseases, but scaling up production to meet demand is challenging. Not only must manufacturers be able to identify potential contaminants, they must be able to do so precisely, reliably and on a predetermined timeline.

Slow-growing bacterial contaminants such as Mycoplasma are particularly difficult to spot. In this webinar, you’ll learn how a new technology and metholdology to detect Mycoplasma contamination in cell cultures can help. This webinar introduces the advantages of Droplet Digital PCR (ddPCR) testing and explains:

• Why CGT research and manufacturing processes are susceptible to contamination
• Why Mycoplasma contamination is so difficult to detect, and the methods that can make it easier
• Current regulatory guidance about Mycoplasma testing  

SPEAKERS

Dipika Gurnani
Global Product Manager of Droplet Digital PCR (ddPCR) Biopharma Solutions
Bio-Rad Laboratories

Jared Schuster
Sr. Regulatory Affairs Associate
NMDP